118 related articles for article (PubMed ID: 22391311)
1. A new era for an ancient drug: arsenic trioxide and Hedgehog signaling.
Beauchamp EM; Uren A
Vitam Horm; 2012; 88():333-54. PubMed ID: 22391311
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway.
Beauchamp EM; Ringer L; Bulut G; Sajwan KP; Hall MD; Lee YC; Peaceman D; Ozdemirli M; Rodriguez O; Macdonald TJ; Albanese C; Toretsky JA; Uren A
J Clin Invest; 2011 Jan; 121(1):148-60. PubMed ID: 21183792
[TBL] [Abstract][Full Text] [Related]
3. Arsenic: a potentially useful poison for Hedgehog-driven cancers.
Raju GP
J Clin Invest; 2011 Jan; 121(1):14-6. PubMed ID: 21183780
[TBL] [Abstract][Full Text] [Related]
4. Molecular targeting therapy against promyelocytic leukemia protein using arsenic acids in experimental intracranial medulloblastoma.
Gu C; Yokota N; Gao Y; Amano S; Koizumi S; Tokuyama T; Namba H
Neurol Med Chir (Tokyo); 2012; 52(2):62-7. PubMed ID: 22362285
[TBL] [Abstract][Full Text] [Related]
5. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.
Kim J; Aftab BT; Tang JY; Kim D; Lee AH; Rezaee M; Kim J; Chen B; King EM; Borodovsky A; Riggins GJ; Epstein EH; Beachy PA; Rudin CM
Cancer Cell; 2013 Jan; 23(1):23-34. PubMed ID: 23291299
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide inhibits the Hedgehog pathway which is aberrantly activated in acute promyelocytic leukemia.
Yang D; Cao F; Ye X; Zhao H; Liu X; Li Y; Shi C; Wang H; Zhou J
Acta Haematol; 2013; 130(4):260-7. PubMed ID: 23867347
[TBL] [Abstract][Full Text] [Related]
7. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector.
Kim J; Lee JJ; Kim J; Gardner D; Beachy PA
Proc Natl Acad Sci U S A; 2010 Jul; 107(30):13432-7. PubMed ID: 20624968
[TBL] [Abstract][Full Text] [Related]
8. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
Vitoux D; Nasr R; de The H
Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
[TBL] [Abstract][Full Text] [Related]
9. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of SHH pathway mechanisms by arsenic trioxide in pediatric medulloblastomas: a comprehensive literature review.
Klinger PH; Andrade AF; Delsin LE; Queiroz RG; Scrideli CA; Tone LG; Valera ET
Genet Mol Res; 2017 Feb; 16(1):. PubMed ID: 28218785
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.
Tallman MS
Blood Rev; 2001 Sep; 15(3):133-42. PubMed ID: 11735161
[No Abstract] [Full Text] [Related]
12. Arsenic trioxide mechanisms of action--looking beyond acute promyelocytic leukemia.
Carney DA
Leuk Lymphoma; 2008 Oct; 49(10):1846-51. PubMed ID: 18949607
[No Abstract] [Full Text] [Related]
13. Co-biomodulation with arsenic trioxide in multiple myeloma.
Gallagher RE
Leuk Res; 2001 Mar; 25(3):237-9. PubMed ID: 11226520
[No Abstract] [Full Text] [Related]
14. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
Soignet SL; Maslak P; Wang ZG; Jhanwar S; Calleja E; Dardashti LJ; Corso D; DeBlasio A; Gabrilove J; Scheinberg DA; Pandolfi PP; Warrell RP
N Engl J Med; 1998 Nov; 339(19):1341-8. PubMed ID: 9801394
[TBL] [Abstract][Full Text] [Related]
15. Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia.
Sui M; Zhang Z; Zhou J
Chin Med J (Engl); 2014; 127(19):3503-6. PubMed ID: 25269921
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase.
Zhang S; Guo W; Ren TT; Lu XC; Tang GQ; Zhao FL
Anticancer Drugs; 2012 Jan; 23(1):108-18. PubMed ID: 21946058
[TBL] [Abstract][Full Text] [Related]
18. Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells.
Petit A; Delaune A; Falluel-Morel A; Goullé JP; Vannier JP; Dubus I; Vasse M
Pharmacol Res; 2013 Nov; 77():11-21. PubMed ID: 24004656
[TBL] [Abstract][Full Text] [Related]
19. What is the role of arsenic in newly diagnosed APL?
Tallman MS
Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.
Smith MA; Kang MH; Reynolds CP; Kurmasheva RT; Alexander D; Billups CA; Toretsky JA; Houghton PJ
Pediatr Blood Cancer; 2012 Oct; 59(4):753-5. PubMed ID: 22315235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
